www.tickerreport.com ·
Proshare Advisors Llc Has 21 44 Million Stake in Bristol Myers Squibb Company Bmy
Topic context
This topic has been covered 235743 times in the last 7 days across our monitored publishers.
The full article is on the original publisher site.
AI insight
AI-generatedThe article reports routine institutional portfolio adjustments and quarterly earnings for Bristol Myers Squibb (BMY). No new drug approvals, pipeline events, regulatory changes, or supply chain disruptions are mentioned. The commercial mechanism is weak: the earnings beat and dividend yield are positive signals for the stock, but there is no concrete impact on product pricing, input costs, or margins beyond normal operations. The primary sector affected is PHARMA_BIOTECH, but the magnitude is low.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- ProShare Advisors LLC increased its stake in Bristol Myers Squibb by 3.5% in Q4, owning 397,535 shares valued at $21.44 million.
- Bristol Myers Squibb reported Q2 2026 earnings of $1.58 per share, beating estimates, with revenue of $11.49 billion.
- The company declared a quarterly dividend of $0.63 per share, yielding 4.3%.
- Institutional investors hold 76.41% of BMY stock.
Related stories
finanznachrichten.de
68617565 zenas biopharma announces submission of biologics license application bla to u s fda for obexelimab in igg4 rd 399
latimes.com
Bitter Slugfest in Central Valley Exposes Divisions in Democratic Party
manilatimes.net
Da Nang Global Business Summit 2026 Silver Generation Innovation Edition
finanznachrichten.de
68616601 lion huynh tran company limited da nang global business summit 2026 silver generation innovation edition 008
cidob.org